Preclinical detection of Alzheimer's disease (AD) is crucial to efficiently recruit clinical trial participants for examining AD‐modifying drugs and ultimately yield clinical benefits for at‐risk individuals. Cerebral amyloidosis precedes synaptic dysfunction and neurodegeneration markers, follow…